Literature DB >> 3982903

Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study.

F Eyal, G Alpan, E Sagi, B Glick, O Peleg, Y Dgani, I Arad.   

Abstract

A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity. In the first part of this study, eight of 15 infants responded to doxapram therapy with complete cessation of apneic spells and six of 11 infants responded similarly to administration of aminophylline. These differences were statistically insignificant. In the second part of the study, assessment was made of whether the addition of doxapram to aminophylline therapy was effective in treatment of apnea of prematurity that had been unresponsive to aminophylline alone. Of ten infants who continued to have apneic spells during treatment with aminophylline, eight responded to the addition of doxapram with complete cessation of apnea. Nine infants received placebo in addition to aminophylline, and none had a reduction in frequency of apnea.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3982903

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Doxapram Treatment for Apnea of Prematurity: A Systematic Review.

Authors:  Roseanne J S Vliegenthart; Christine H Ten Hove; Wes Onland; Anton H L C van Kaam
Journal:  Neonatology       Date:  2016-10-20       Impact factor: 4.035

Review 2.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.

Authors:  E Greze; M Benard; I Hamon; C Casper; F E Haddad; M-J Boutroy; J-M Hascoët
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

4.  Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

Authors:  Yuki Ogawa; Mitsuru Irikura; Yuka Kobaru; Mayu Tomiyasu; Yoshie Kochiyama; Mamiko Uriu; Yoichi Ishitsuka; Yuki Kondo; Eiji Yukawa; Noboru Kamada; Hitoshi Ohno; Toshio Yamazaki; Tetsumi Irie
Journal:  Eur J Pediatr       Date:  2014-09-25       Impact factor: 3.183

5.  The bioavailability and maturing clearance of doxapram in preterm infants.

Authors:  Robert B Flint; Sinno H P Simons; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Irwin K M Reiss; Rob Ter Heine; Aline G J Engbers; Birgit C P Koch; Ronald de Groot; David M Burger; Catherijne A J Knibbe; Swantje Völler
Journal:  Pediatr Res       Date:  2020-07-22       Impact factor: 3.756

6.  Doxapram use for apnoea of prematurity in neonatal intensive care.

Authors:  S A Prins; S J A Pans; M M van Weissenbruch; F J Walther; S H P Simons
Journal:  Int J Pediatr       Date:  2013-11-26

7.  Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.

Authors:  Eilan Alhersh; Dina Abushanab; Samaher Al-Shaibi; Daoud Al-Badriyeh
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.